↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Seaport Entertainment Group$SEG · filed: grew revenue 18.3% in FY2025 to $130MOld boatNext year $118M–$169M sealedCheck ▾Close ▴
What Seaport Entertainment Group filed
Grew revenue 18.3% in FY2025 to $130 million, operating margin -90.6% against a 7.0% median for miscellaneous amusement & recreation, equity 70.2% of assets. Every figure links to the filing it came from on Seaport Entertainment Group’s card. Old boat: three warning signs.
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $118M and $169M, an 80% range sealed on 27 Sept 2026 · receipt #6562a9 · graded in public by the revenue in Seaport Entertainment Group’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Three biotech IPO filings in eight days test allocator appetite after 18-month freeze, with Kailera pricing at low-end signaling caution.
$106 million
at the low end of range—a signal that institutional…
$10 per share
is developing therapies for chronic kidney disease and raised…
4.2x
trailing twelve-month R&
18-month
drought in biotech IPO velocity
Seaport Therapeutics and Hemab Therapeutics filed for initial public offerings this week, joining Kailera Therapeutics in a cluster of biotech IPO activity that represents the first sustained filing momentum since mid-2023. Kailera priced its offering Wednesday, raising $106 million at the low end of range—a signal that institutional allocators are willing to participate, but not at premium.
Seaport, a clinical-stage neuroscience company spun out of Karuna Therapeutics, disclosed its S-1 filing Thursday with plans to list on Nasdaq. The company is developing treatments for psychiatric and neurological disorders, led by SPN-830, a Phase 3-stage therapy for post-traumatic stress disorder. Hemab, focused on hemophilia A treatments, filed Friday with no disclosed pricing terms yet. Neither company named lead underwriters in initial filings, a procedural lag that typically resolves within two weeks. Kailera, which priced at $10 per share, is developing therapies for chronic kidney disease and raised capital at a valuation that values the company at roughly 4.2x trailing twelve-month R&D spend—compressed by historical biotech IPO standards but in line with 2024's risk-off pricing environment.
The cluster matters because it breaks an 18-month drought in biotech IPO velocity. Since Q2 2023, only a handful of life sciences companies have gone public, with most venture-backed biotechs choosing private extension rounds or strategic acquisitions over public markets. The sudden filing activity suggests three possible dynamics: syndicate desks testing allocation appetite ahead of a potential spring window, companies with clinical catalysts in the next 12-18 months choosing to front-run volatile macro conditions, or venture portfolios reaching fund-life limits that force liquidity events regardless of pricing. Seaport's filing is particularly instructive—Karuna itself was acquired by Bristol-Myers Squibb for $14 billion in late 2023, and Seaport represents the neuroscience pipeline assets that didn't fit the acquirer's development strategy. Spinning out post-acquisition assets into standalone IPOs is a pattern that typically signals sponsor conviction, but also reflects limited M&A appetite for mid-stage programs in the current environment.
Allocators should watch three follow-on data points. First, whether Seaport and Hemab price within 21 days of filing or delay into Q2, which would indicate institutional pushback on valuation or terms. Second, the composition of cornerstone investors in these deals—if mutual funds or crossover hedge funds anchor the books, it signals broader risk-on rotation; if only specialist biotech funds participate, the rally is narrow. Third, post-IPO trading performance of Kailera over the next 30 days—if shares hold or trade up, the IPO window widens materially; if they break issue price, the window was a headfake. The broader venture intelligence takeaway is that biotech syndicates are testing the market, not leading it.
Seaport's Phase 3 PTSD data is expected in mid-2025, which places the IPO roughly 9-12 months ahead of a binary value catalyst—tight timing that leaves little room for clinical delays or enrollment misses.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
